About 15 to 20 percent of breast tumors are triple-negative breast cancers (TNBC), which are defined by the absence of the progesterone receptor (PR), estrogen receptor (ER) and human epidermal growth factor receptor 2(HER2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.